Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 16 Researches
7.9
USERS' SCORE
Good
Based on 6 Reviews
8.1
Supplement Facts
Serving Size: 1 Caplet
Amount Per Serving
%DV
Organic ashwagandha powder (root)(0.2% Withanolides, 0.76 mg)
380 mg
*
Organic ashwagandha extract (root)(0.5% Withanolides, 1.4 mg)
280 mg
*
Organic ashwagandha supercriticalCO2 extract (root) (Withania somnifera) (8% Withanolides, 0.8 mg)
10 mg
*
Top Medical Research Studies
9
We set out to explore how docosahexaenoic acid (DHA), a type of omega-3 fatty acid, affects colorectal cancer (CRC) cells. In this study, we treated five different colorectal cancer cell lines with varying concentrations of DHA, along with other fatty acids like eicosapentaenoic acid (EPA) and linoleic acid (LA). This allowed us to see if DHA could impact the methylation patterns of the PPARγ promoter, a key player in cancer regulation, and affect the relationship between PPARγ and COX2, two important molecules involved in cancer growth.
Our findings revealed that DHA significantly altered the methylation status in some cell lines, effectively demethylating specific regions of the PPARγ promoter. We observed that this demethylation was linked to an increase in the expression of PPARγ in cells where it was hemimethylated. Interestingly, DHA not only boosted PPARγ levels but also downregulated COX2 across all CRC cell lines tested. This suggests that DHA might have a role in reducing inflammatory signals linked to cancer progression.
The overall impact seemed to vary depending on the type of cancer cell we were working with, indicating a cell type-dependent effect of DHA. Notably, we found that DHA was more effective than EPA or LA in modulating the PPARγ promoter. This research shows promising potential for DHA in colorectal cancer treatment and highlights its importance in dietary considerations for cancer management.
Our findings revealed that DHA significantly altered the methylation status in some cell lines, effectively demethylating specific regions of the PPARγ promoter. We observed that this demethylation was linked to an increase in the expression of PPARγ in cells where it was hemimethylated. Interestingly, DHA not only boosted PPARγ levels but also downregulated COX2 across all CRC cell lines tested. This suggests that DHA might have a role in reducing inflammatory signals linked to cancer progression.
The overall impact seemed to vary depending on the type of cancer cell we were working with, indicating a cell type-dependent effect of DHA. Notably, we found that DHA was more effective than EPA or LA in modulating the PPARγ promoter. This research shows promising potential for DHA in colorectal cancer treatment and highlights its importance in dietary considerations for cancer management.
Read More
8
Docosahexaenoic acid and breast cancer
We conducted an exciting study to understand how docosahexaenoic acid (DHA), a type of n-3 fatty acid, affects women who are survivors of estrogen receptor and progesterone receptor negative (ERPR-) breast cancer. This particular molecular subtype of breast cancer is known for its unique challenges, and dietary fat choices may influence its progression.
Over the course of one year, participants in our clinical trial received different doses of EPA and DHA, ranging from about 1 to 5 grams per day. We gathered blood and breast fat tissue samples at various points during the study to analyze changes in fatty acids, specifically looking at how these doses affected fatty acid levels and related compounds called oxylipins, which are involved in inflammation and cancer processes.
Our findings revealed that the higher doses of EPA and DHA led to increased levels of these fatty acids in breast fat tissue. Moreover, we observed changes in the DNA methylation patterns related to metabolic pathways in breast cancer. This suggests that DHA and EPA may play a role beyond mere nutrition, potentially influencing genetic expression related to cancer risk.
Overall, our research highlights the metabolic and epigenetic effects of n-3 fatty acids in managing ERPR- breast cancer. The study opens up new avenues for exploring how dietary choices may help prevent this aggressive form of breast cancer.
Over the course of one year, participants in our clinical trial received different doses of EPA and DHA, ranging from about 1 to 5 grams per day. We gathered blood and breast fat tissue samples at various points during the study to analyze changes in fatty acids, specifically looking at how these doses affected fatty acid levels and related compounds called oxylipins, which are involved in inflammation and cancer processes.
Our findings revealed that the higher doses of EPA and DHA led to increased levels of these fatty acids in breast fat tissue. Moreover, we observed changes in the DNA methylation patterns related to metabolic pathways in breast cancer. This suggests that DHA and EPA may play a role beyond mere nutrition, potentially influencing genetic expression related to cancer risk.
Overall, our research highlights the metabolic and epigenetic effects of n-3 fatty acids in managing ERPR- breast cancer. The study opens up new avenues for exploring how dietary choices may help prevent this aggressive form of breast cancer.
Read More
9.5
DHA shows promise against neuroblastoma
We conducted a study to explore the effects of docosahexaenoic acid (DHA) on tumor formation, particularly in a mouse model of neuroblastoma—a type of aggressive cancer in children. By using a syngeneic model, we gavaged wildtype mice with high doses of omega-3 fatty acids, including DHA, and then injected cancerous cells to monitor tumor development.
In our experiment, we noticed that while 50% of untreated control mice developed tumors, those receiving high doses of DHA or its oxidation-resistant form completely avoided tumor formation. This was quite striking and contrasts with our findings regarding arachidonic acid (ARA), which actually seemed to enhance tumor growth. Notably, when we combined ARA with EPA (another fatty acid), it led to a lower tumor burden, suggesting that DHA acts through a different, non-oxidative mechanism.
These results suggest that high-dose DHA may offer a promising, low-toxicity therapy option for neuroblastoma, paving the way for safer future treatments. It’s exciting to see the potential of omega-3 fatty acids in cancer prevention, especially given their safety and tolerability in humans over extended periods.
In our experiment, we noticed that while 50% of untreated control mice developed tumors, those receiving high doses of DHA or its oxidation-resistant form completely avoided tumor formation. This was quite striking and contrasts with our findings regarding arachidonic acid (ARA), which actually seemed to enhance tumor growth. Notably, when we combined ARA with EPA (another fatty acid), it led to a lower tumor burden, suggesting that DHA acts through a different, non-oxidative mechanism.
These results suggest that high-dose DHA may offer a promising, low-toxicity therapy option for neuroblastoma, paving the way for safer future treatments. It’s exciting to see the potential of omega-3 fatty acids in cancer prevention, especially given their safety and tolerability in humans over extended periods.
Read More
Most Useful Reviews
9
Aid during treatment
This brand helped significantly during my battle with cancer. After years of consistent use, I believe the quality remains high. The caplets may have a strong odour, but with water, I manage to take them without any issues.
Read More
7.5
Mood enhancement
1 people found this helpful
I purchased this primarily to support my cancer fight, but it has significantly improved my mood and sleep too. I will certainly continue using it!
Read More
6
Post-surgery support
I have found it effective in managing anxiety following the removal of tissue due to cancer surgery.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 16 Researches
7.9
- All Researches
9.5
DHA shows promise against neuroblastoma
We conducted a study to explore the effects of docosahexaenoic acid (DHA) on tumor formation, particularly in a mouse model of neuroblastoma—a type of aggressive cancer in children. By using a syngeneic model, we gavaged wildtype mice with high doses of omega-3 fatty acids, including DHA, and then injected cancerous cells to monitor tumor development.
In our experiment, we noticed that while 50% of untreated control mice developed tumors, those receiving high doses of DHA or its oxidation-resistant form completely avoided tumor formation. This was quite striking and contrasts with our findings regarding arachidonic acid (ARA), which actually seemed to enhance tumor growth. Notably, when we combined ARA with EPA (another fatty acid), it led to a lower tumor burden, suggesting that DHA acts through a different, non-oxidative mechanism.
These results suggest that high-dose DHA may offer a promising, low-toxicity therapy option for neuroblastoma, paving the way for safer future treatments. It’s exciting to see the potential of omega-3 fatty acids in cancer prevention, especially given their safety and tolerability in humans over extended periods.
In our experiment, we noticed that while 50% of untreated control mice developed tumors, those receiving high doses of DHA or its oxidation-resistant form completely avoided tumor formation. This was quite striking and contrasts with our findings regarding arachidonic acid (ARA), which actually seemed to enhance tumor growth. Notably, when we combined ARA with EPA (another fatty acid), it led to a lower tumor burden, suggesting that DHA acts through a different, non-oxidative mechanism.
These results suggest that high-dose DHA may offer a promising, low-toxicity therapy option for neuroblastoma, paving the way for safer future treatments. It’s exciting to see the potential of omega-3 fatty acids in cancer prevention, especially given their safety and tolerability in humans over extended periods.
Read More
9
We set out to explore how docosahexaenoic acid (DHA), a type of omega-3 fatty acid, affects colorectal cancer (CRC) cells. In this study, we treated five different colorectal cancer cell lines with varying concentrations of DHA, along with other fatty acids like eicosapentaenoic acid (EPA) and linoleic acid (LA). This allowed us to see if DHA could impact the methylation patterns of the PPARγ promoter, a key player in cancer regulation, and affect the relationship between PPARγ and COX2, two important molecules involved in cancer growth.
Our findings revealed that DHA significantly altered the methylation status in some cell lines, effectively demethylating specific regions of the PPARγ promoter. We observed that this demethylation was linked to an increase in the expression of PPARγ in cells where it was hemimethylated. Interestingly, DHA not only boosted PPARγ levels but also downregulated COX2 across all CRC cell lines tested. This suggests that DHA might have a role in reducing inflammatory signals linked to cancer progression.
The overall impact seemed to vary depending on the type of cancer cell we were working with, indicating a cell type-dependent effect of DHA. Notably, we found that DHA was more effective than EPA or LA in modulating the PPARγ promoter. This research shows promising potential for DHA in colorectal cancer treatment and highlights its importance in dietary considerations for cancer management.
Our findings revealed that DHA significantly altered the methylation status in some cell lines, effectively demethylating specific regions of the PPARγ promoter. We observed that this demethylation was linked to an increase in the expression of PPARγ in cells where it was hemimethylated. Interestingly, DHA not only boosted PPARγ levels but also downregulated COX2 across all CRC cell lines tested. This suggests that DHA might have a role in reducing inflammatory signals linked to cancer progression.
The overall impact seemed to vary depending on the type of cancer cell we were working with, indicating a cell type-dependent effect of DHA. Notably, we found that DHA was more effective than EPA or LA in modulating the PPARγ promoter. This research shows promising potential for DHA in colorectal cancer treatment and highlights its importance in dietary considerations for cancer management.
Read More
9
We assessed the effectiveness of docosahexaenoic acid (DHA) in treating cancer, specifically in various rodent models of hepatocellular carcinoma (HCC). The study utilized weighted amide proton transfer (APT) MRI to monitor tumor response in three different HCC models: diethylnitrosamine (DEN) induced HCC, N1S1 syngeneic orthotopic xenograft, and human HepG2 ectopic xenograft.
Our findings revealed that all HCC models exhibited a markedly higher APT signal compared to surrounding normal tissues. This increased signal allowed us to distinguish between malignant HCC lesions and benign nodules specifically in the DEN model.
By administering low-density lipoprotein docosahexaenoic acid (LDL-DHA) nanoparticles directly to N1S1 xenografts, we observed a significant reduction in tumor APT signal within just 72 hours. Similarly, direct injections into HepG2 xenografts demonstrated comparable therapeutic effects. Overall, this study showcases the potential of APT imaging in the diagnostic and therapeutic management of HCC, particularly highlighting DHA's effectiveness delivered via nanoparticles.
Our findings revealed that all HCC models exhibited a markedly higher APT signal compared to surrounding normal tissues. This increased signal allowed us to distinguish between malignant HCC lesions and benign nodules specifically in the DEN model.
By administering low-density lipoprotein docosahexaenoic acid (LDL-DHA) nanoparticles directly to N1S1 xenografts, we observed a significant reduction in tumor APT signal within just 72 hours. Similarly, direct injections into HepG2 xenografts demonstrated comparable therapeutic effects. Overall, this study showcases the potential of APT imaging in the diagnostic and therapeutic management of HCC, particularly highlighting DHA's effectiveness delivered via nanoparticles.
Read More
9
In our research, we looked into the potential benefits of docosahexaenoic acid, a type of omega-3 fatty acid, in treating pancreatic cancer. Utilizing a mouse model that closely mirrors the human disease, we examined how a diet rich in omega-3 fatty acids—specifically eicosapentaenoic acid and docosahexaenoic acid—affects tumor growth and metastasis.
We observed that mice on a diet supplemented with cod liver oil, which is high in omega-3s, exhibited a notable decrease in tumor size and lung and liver metastasis compared to control mice. The treatment seemed to enhance survival rates, suggesting that these fatty acids may help combat the growth of cancerous tumors.
Moreover, our findings indicated changes in the tumor's fatty acid profile and the release of eicosanoids, which are important signaling molecules in cancer. The intervention also reduced key histological features of malignancy and promoted apoptosis, or programmed cell death, without impacting the rate of cell proliferation. This indicates that omega-3 fatty acids might act in ways other than just slowing down cell division.
We noted a significant reduction in tumor fibrosis, which is often associated with aggressive cancer forms. This was linked to lower levels of Sonic Hedgehog, a protein playing a central role in tumor development. Overall, our study highlights the promise of docosahexaenoic acid and its fellow omega-3 fatty acids as potential dietary tools in pancreatic cancer treatment, paving the way for incorporating nutritional strategies into cancer care.
We observed that mice on a diet supplemented with cod liver oil, which is high in omega-3s, exhibited a notable decrease in tumor size and lung and liver metastasis compared to control mice. The treatment seemed to enhance survival rates, suggesting that these fatty acids may help combat the growth of cancerous tumors.
Moreover, our findings indicated changes in the tumor's fatty acid profile and the release of eicosanoids, which are important signaling molecules in cancer. The intervention also reduced key histological features of malignancy and promoted apoptosis, or programmed cell death, without impacting the rate of cell proliferation. This indicates that omega-3 fatty acids might act in ways other than just slowing down cell division.
We noted a significant reduction in tumor fibrosis, which is often associated with aggressive cancer forms. This was linked to lower levels of Sonic Hedgehog, a protein playing a central role in tumor development. Overall, our study highlights the promise of docosahexaenoic acid and its fellow omega-3 fatty acids as potential dietary tools in pancreatic cancer treatment, paving the way for incorporating nutritional strategies into cancer care.
Read More
8
We explored the relationship between docosahexaenoic acid (DHA) and its effects on cancer treatment, particularly focusing on its role alongside anti-PD-L1 therapy for melanoma. The study employed a humanized gnotobiotic mouse model to better understand how dietary components influence gut microbiota and their metabolites in the context of cancer immunotherapy.
Our findings revealed that ginger-derived exosome-like nanoparticles (GELN) specifically targeted certain gut bacteria, enhancing their function. Notably, we discovered that the incorporation of GELN into treatment increased levels of DHA. Elevated DHA levels were found to inhibit PD-L1 expression in tumor cells by binding to its promoter, thus disrupting a process that often leads to cancer proliferation.
Furthermore, we observed that germ-free mice colonized with gut bacteria from individuals who did not respond to anti-PD-L1 therapy showed improved treatment responses when supplemented with DHA. This suggests that manipulating gut microbiota and metabolites could bolster cancer immunotherapy efforts.
Overall, our study shines a light on the significant role that dietary elements like DHA play in enhancing the efficacy of immunotherapies in cancer treatment, offering promising avenues for future research and therapeutic strategies.
Our findings revealed that ginger-derived exosome-like nanoparticles (GELN) specifically targeted certain gut bacteria, enhancing their function. Notably, we discovered that the incorporation of GELN into treatment increased levels of DHA. Elevated DHA levels were found to inhibit PD-L1 expression in tumor cells by binding to its promoter, thus disrupting a process that often leads to cancer proliferation.
Furthermore, we observed that germ-free mice colonized with gut bacteria from individuals who did not respond to anti-PD-L1 therapy showed improved treatment responses when supplemented with DHA. This suggests that manipulating gut microbiota and metabolites could bolster cancer immunotherapy efforts.
Overall, our study shines a light on the significant role that dietary elements like DHA play in enhancing the efficacy of immunotherapies in cancer treatment, offering promising avenues for future research and therapeutic strategies.
Read More
User Reviews
USERS' SCORE
Good
Based on 6 Reviews
8.1
- All Reviews
- Positive Reviews
- Negative Reviews
9
Aid during treatment
This brand helped significantly during my battle with cancer. After years of consistent use, I believe the quality remains high. The caplets may have a strong odour, but with water, I manage to take them without any issues.
Read More
7.5
Mood enhancement
1 people found this helpful
I purchased this primarily to support my cancer fight, but it has significantly improved my mood and sleep too. I will certainly continue using it!
Read More
6
Post-surgery support
I have found it effective in managing anxiety following the removal of tissue due to cancer surgery.
Read More
7.5
Reduces anxiety levels
70 people found this helpful
It assists the body in alleviating stress and anxiety, possesses anti-cancer properties, and lowers blood levels.
Read More
7.5
Supports brain health
12 people found this helpful
Ashwagandha beans are a well-established herb in alternative medicine, utilised for over 2,500 years in India. It is praised for its benefits on the nervous system and thyroid, reducing anxiety, depression, and inflammation. Its properties include increasing focus, enhancing memory, and offering anticancer benefits, all while strengthening the immune system.
Read More
Frequently Asked Questions
9
Aid during treatment
This brand helped significantly during my battle with cancer. After years of consistent use, I believe the quality remains high. The caplets may have a strong odour, but with water, I manage to take them without any issues.
6
Post-surgery support
I have found it effective in managing anxiety following the removal of tissue due to cancer surgery.
7.5
Reduces anxiety levels
70 people found this helpful
It assists the body in alleviating stress and anxiety, possesses anti-cancer properties, and lowers blood levels.
7.5
Supports brain health
12 people found this helpful
Ashwagandha beans are a well-established herb in alternative medicine, utilised for over 2,500 years in India. It is praised for its benefits on the nervous system and thyroid, reducing anxiety, depression, and inflammation. Its properties include increasing focus, enhancing memory, and offering anticancer benefits, all while strengthening the immune system.
7.5
Lowers blood sugar
8 people found this helpful
I found this product to be terrible yet highly recommend it. Top benefits include lowering blood sugar levels, cortisol levels, alleviating depression, and cancer-fighting properties, along with reducing stress and anxiety.
7
DHA's potential in cancer therapy
In our exploration of liver cancer treatment, we found that combinations of Lenvatinib—an established first-line therapy—and docosahexaenoic acid (DHA) can uniquely influence outcomes. The focus was on understanding how Lenvatinib resistance develops in hepatocellular carcinoma (HCC) and the potential role of DHA in this context.
Through comprehensive studies, including CRISPR screening in liver cancer cells, we discovered that a protein called DTX2 strongly contributes to Lenvatinib resistance. This protein helps protect the cancer cells from a type of cell death known as ferroptosis, which Lenvatinib usually triggers. Interestingly, we learned that DTX2 does this by reducing DHA levels, a fatty acid that plays a crucial role in cellular health.
In our findings, when we added DHA to Lenvatinib treatment, it appeared to counteract DTX2's protective effect against ferroptosis. The study emphasized that using DHA in combination with Lenvatinib could potentially offer a new therapeutic pathway for patients facing drug resistance in liver cancer.
Overall, the relationship between DTX2, DHA production, and Lenvatinib resistance presents an exciting avenue for further exploration in cancer treatment strategies.
Through comprehensive studies, including CRISPR screening in liver cancer cells, we discovered that a protein called DTX2 strongly contributes to Lenvatinib resistance. This protein helps protect the cancer cells from a type of cell death known as ferroptosis, which Lenvatinib usually triggers. Interestingly, we learned that DTX2 does this by reducing DHA levels, a fatty acid that plays a crucial role in cellular health.
In our findings, when we added DHA to Lenvatinib treatment, it appeared to counteract DTX2's protective effect against ferroptosis. The study emphasized that using DHA in combination with Lenvatinib could potentially offer a new therapeutic pathway for patients facing drug resistance in liver cancer.
Overall, the relationship between DTX2, DHA production, and Lenvatinib resistance presents an exciting avenue for further exploration in cancer treatment strategies.
9
We set out to explore how docosahexaenoic acid (DHA), a type of omega-3 fatty acid, affects colorectal cancer (CRC) cells. In this study, we treated five different colorectal cancer cell lines with varying concentrations of DHA, along with other fatty acids like eicosapentaenoic acid (EPA) and linoleic acid (LA). This allowed us to see if DHA could impact the methylation patterns of the PPARγ promoter, a key player in cancer regulation, and affect the relationship between PPARγ and COX2, two important molecules involved in cancer growth.
Our findings revealed that DHA significantly altered the methylation status in some cell lines, effectively demethylating specific regions of the PPARγ promoter. We observed that this demethylation was linked to an increase in the expression of PPARγ in cells where it was hemimethylated. Interestingly, DHA not only boosted PPARγ levels but also downregulated COX2 across all CRC cell lines tested. This suggests that DHA might have a role in reducing inflammatory signals linked to cancer progression.
The overall impact seemed to vary depending on the type of cancer cell we were working with, indicating a cell type-dependent effect of DHA. Notably, we found that DHA was more effective than EPA or LA in modulating the PPARγ promoter. This research shows promising potential for DHA in colorectal cancer treatment and highlights its importance in dietary considerations for cancer management.
Our findings revealed that DHA significantly altered the methylation status in some cell lines, effectively demethylating specific regions of the PPARγ promoter. We observed that this demethylation was linked to an increase in the expression of PPARγ in cells where it was hemimethylated. Interestingly, DHA not only boosted PPARγ levels but also downregulated COX2 across all CRC cell lines tested. This suggests that DHA might have a role in reducing inflammatory signals linked to cancer progression.
The overall impact seemed to vary depending on the type of cancer cell we were working with, indicating a cell type-dependent effect of DHA. Notably, we found that DHA was more effective than EPA or LA in modulating the PPARγ promoter. This research shows promising potential for DHA in colorectal cancer treatment and highlights its importance in dietary considerations for cancer management.
8
Docosahexaenoic acid reduces cancer risk
We examined the relationship between docosahexaenoic acid (DHA), a type of omega-3 fatty acid, and colorectal cancer risk using data from the UK Biobank study. This study included over 234,000 participants and tracked health outcomes over a mean follow-up of 13.4 years, focusing specifically on blood levels of DHA and overall n-3 polyunsaturated fatty acids (PUFAs).
Our findings showed that higher levels of plasma n-3 PUFAs and DHA were linked to a decreased risk of developing colorectal cancer. The analysis suggested a non-linear relationship, meaning that while increasing levels of these fatty acids generally led to lower cancer risk, the beneficial effects plateaued at higher concentrations. This trend was particularly noteworthy for cancers located in the proximal colon and was more pronounced among male participants.
While the study highlights the potential protective effects of DHA against colorectal cancer, it's important to acknowledge that the relationship varied based on tumor location and participant sex. This insight could help shape nutrition guidelines, should these findings hold true across broader populations.
Our findings showed that higher levels of plasma n-3 PUFAs and DHA were linked to a decreased risk of developing colorectal cancer. The analysis suggested a non-linear relationship, meaning that while increasing levels of these fatty acids generally led to lower cancer risk, the beneficial effects plateaued at higher concentrations. This trend was particularly noteworthy for cancers located in the proximal colon and was more pronounced among male participants.
While the study highlights the potential protective effects of DHA against colorectal cancer, it's important to acknowledge that the relationship varied based on tumor location and participant sex. This insight could help shape nutrition guidelines, should these findings hold true across broader populations.
9.5
DHA shows promise against neuroblastoma
We conducted a study to explore the effects of docosahexaenoic acid (DHA) on tumor formation, particularly in a mouse model of neuroblastoma—a type of aggressive cancer in children. By using a syngeneic model, we gavaged wildtype mice with high doses of omega-3 fatty acids, including DHA, and then injected cancerous cells to monitor tumor development.
In our experiment, we noticed that while 50% of untreated control mice developed tumors, those receiving high doses of DHA or its oxidation-resistant form completely avoided tumor formation. This was quite striking and contrasts with our findings regarding arachidonic acid (ARA), which actually seemed to enhance tumor growth. Notably, when we combined ARA with EPA (another fatty acid), it led to a lower tumor burden, suggesting that DHA acts through a different, non-oxidative mechanism.
These results suggest that high-dose DHA may offer a promising, low-toxicity therapy option for neuroblastoma, paving the way for safer future treatments. It’s exciting to see the potential of omega-3 fatty acids in cancer prevention, especially given their safety and tolerability in humans over extended periods.
In our experiment, we noticed that while 50% of untreated control mice developed tumors, those receiving high doses of DHA or its oxidation-resistant form completely avoided tumor formation. This was quite striking and contrasts with our findings regarding arachidonic acid (ARA), which actually seemed to enhance tumor growth. Notably, when we combined ARA with EPA (another fatty acid), it led to a lower tumor burden, suggesting that DHA acts through a different, non-oxidative mechanism.
These results suggest that high-dose DHA may offer a promising, low-toxicity therapy option for neuroblastoma, paving the way for safer future treatments. It’s exciting to see the potential of omega-3 fatty acids in cancer prevention, especially given their safety and tolerability in humans over extended periods.
References
- Zhang Z, Zhou Q, Li Z, Huang F, Mo K, et al. DTX2 attenuates Lenvatinib-induced ferroptosis by suppressing docosahexaenoic acid biosynthesis through HSD17B4-dependent peroxisomal β-oxidation in hepatocellular carcinoma. Drug Resist Updat. 2025;81:101224. doi:10.1016/j.drup.2025.101224
- Babaeenezhad E, Khosravi P, Moradi Sarabi M. Dietary polyunsaturated fatty acids affect PPARγ promoter methylation status and regulate the PPARγ/COX2 pathway in some colorectal cancer cell lines. Genes Nutr. 2025;20:2. doi:10.1186/s12263-025-00764-x
- Patel V, Li YN, Benhamou LE, Park HG, Raleigh M, et al. Ultra-High Dose Oral ω3 Eicosapentaenoic Acid (EPA), Docosahexaenoic Acid (DHA), or Oxidation-Resistant Deuterated DHA Block Tumorigenesis in a -Driven Neuroblastoma Model. Cancers (Basel). 2025;17. doi:10.3390/cancers17030362
- Teng Y, Luo C, Qiu X, Mu J, Sriwastva MK, et al. Plant-nanoparticles enhance anti-PD-L1 efficacy by shaping human commensal microbiota metabolites. Nat Commun. 2025;16:1295. doi:10.1038/s41467-025-56498-2
- Wang X, Ishimatsu K, Li J, Wen X, Ou W, et al. APT imaging of hepatocellular carcinoma signals an effective therapeutic response in advance of tumor shrinkage. Hepat Oncol. 2024;11:2389031. doi:10.1080/20450923.2024.2389031
- Olkhovik DM, Silkina MO, Razumovskaya AV, Klycheva KV, Fatkulin AA, et al. Omega-3 Docosahexaenoic Acid as a Promising Inducer of Ferroptosis: Dynamics of Action in Prostate and Colorectal Cancer Models. Dokl Biochem Biophys. 2025. doi:10.1134/S160767292460132X
- Garay MI, Mazo T, Ferrero V, Barotto NN, Lagares C, et al. Novel inhibitory effect of Omega-3 fatty acids regulating pancreatic cancer progression. Carcinogenesis. 2025;46. doi:10.1093/carcin/bgae081
- Aldoori J, Zulyniak MA, Toogood GJ, Hull MA. Plasma n-3 Polyunsaturated Fatty Acid Levels and Colorectal Cancer Risk in the UK Biobank: Evidence of Nonlinearity, as Well as Tumor Site- and Sex-Specificity. Cancer Epidemiol Biomarkers Prev. 2025;34:394. doi:10.1158/1055-9965.EPI-24-1154
- Lin HL, Lin QY, Feng JN, Zheng WE, Yang C, et al. Plasma fatty acid levels and risk of non-small cell lung cancer: a large-scale prospective cohort study. Front Nutr. 2024;11:1462300. doi:10.3389/fnut.2024.1462300
- Frankhouser DE, DeWess T, Snodgrass IF, Cole RM, Steck S, et al. Randomized dose-response trial of n-3 fatty acids in hormone receptor negative breast cancer survivors- impact on breast adipose oxylipin and DNA methylation patterns. medRxiv. 2024. doi:10.1101/2024.09.16.24313691
- Ormiston K, Fitzgerald J, Andridge R, Lustberg MB, DeVries AC, et al. Low sucrose diets protect long-term memory and EPA & DHA enriched diets alter insulin resistance in a mouse model of chemotherapy. Nutr Res. 2024;131:39. doi:10.1016/j.nutres.2024.09.004
- Ormiston K, Melink Z, Andridge R, Lustberg M, Courtney DeVries A, et al. Dietary EPA and DHA enrichment of a high fat diet during doxorubicin-based chemotherapy attenuated neuroinflammatory gene expression in the brain of C57bl/6 ovariectomized mice. Brain Behav Immun. 2025;123:370. doi:10.1016/j.bbi.2024.09.021
- La Vecchia S, Fontana S, Salaroglio IC, Anobile DP, Digiovanni S, et al. Increasing membrane polyunsaturated fatty acids sensitizes non-small cell lung cancer to anti-PD-1/PD-L1 immunotherapy. Cancer Lett. 2024;604:217221. doi:10.1016/j.canlet.2024.217221
- Huang J, Li J, He L, Miao J, Zhu M, et al. The association between plasma fatty acids and risk of lung cancer: a prospective cohort study of the UK Biobank. J Clin Endocrinol Metab. 2024. doi:10.1210/clinem/dgae609
- Lin SC, Tsai YC, Chen YL, Lin HK, Huang YC, et al. Un-methylation of NUDT21 represses docosahexaenoic acid biosynthesis contributing to enzalutamide resistance in prostate cancer. Drug Resist Updat. 2024;77:101144. doi:10.1016/j.drup.2024.101144
- Chua AV, Hernandez ARB, Mendoza MJL, San Juan MD. Omega-3 Fatty Acids Increase Weight and Quality of Life Scores in Patients With Advanced Non-Small Cell Lung Cancer and Cancer Cachexia: A Meta-Analysis. Integr Cancer Ther. 2024;23:15347354241275052. doi:10.1177/15347354241275052
